Adrenocortical carcinoma: the management of metastatic disease
- PMID: 24958272
- PMCID: PMC4578298
- DOI: 10.1016/j.critrevonc.2014.05.009
Adrenocortical carcinoma: the management of metastatic disease
Abstract
Adrenocortical cancer is a rare malignancy. While surgery is the cornerstone of the management of localized disease, metastatic disease is hard to treat. Cytotoxic chemotherapy and mitotane have been utilized with a variable degree of benefit and few long-term responses. A growing understanding of the molecular pathogenesis of this malignancy as well as multidisciplinary and multi-institutional collaborative efforts will result in better defined targets and subsequently, effective novel therapies.
Keywords: Adrenocortical carcinoma; Metastatic disease; Targeted therapies; Therapeutics.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
References
-
- Third national cancer survey: incidence data. National Cancer Institute monograph. 1975 Mar;(41):i–x. 1–454. - PubMed
-
- Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World journal of surgery. 2006 May;30(5):872–878. - PubMed
-
- Koschker AC, Fassnacht M, Hahner S, Weismann D, Allolio B. Adrenocortical carcinoma -- improving patient care by establishing new structures. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 2006 Feb;114(2):45–51. - PubMed
-
- Pianovski MA, Maluf EM, de Carvalho DS, et al. Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil. Pediatric blood & cancer. 2006 Jul;47(1):56–60. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources